Newsletter | January 14, 2022

01.14.22 -- Why Qlaris Bio Is Our Company To Watch

 
Exclusive Articles
The Challenges — And Opportunities — Facing The European Biotech Industry
 

Converting cutting-edge research into viable products remains a challenge for the European biotech sector. Jonathan Hay of Delin Ventures investigates how ambition can translate to reality.

Companies To Watch: Qlaris Bio
 

Qlaris Bio is striking at an unaddressed target in the intraocular pressure of glaucoma.

Why The Best Leaders Move Slowly
 

The best CEOs often find ways to slow down when facing daily challenges, which allows them to respond more appropriately and purposeful.

Web-Exclusive Content
A Firsthand Account: The Evolution, Challenge, And Hope Of CAR-T Therapy
 

The questions before us: Can we manufacture treatments safely and at scale? Can we make the treatments affordable so cancer patients can access them more quickly?

Industry Insights
Achieving Cell And Gene Manufacturing Scalability: A Conversation With AVROBIO’s Geoff MacKay

Geoff MacKay, president and CEO of AVROBIO, talks with The Business of Biotech podcast about the scale-up obstacles facing the cell and gene therapy space and how AVRO is working to tackle them.

January 2022 Digital Edition
 

Inside you will find more on:

  • Employee Retention
  • CEO Corner
  • Ask The Board
  • Cell Therapy Roadblocks

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines
 

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.